To formally assess the role of GSL metabolism in KRAS oncogenesis, we treated multiple KRAS mutant pancreatic cancer cell lines and a non-transformed pancreatic epithelial cell strain with a UGCG inhibitor. The gene discussed is KRAS; the disease is pancreatic neoplasm.